1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > Cervical Cancer - Pipeline Review, H1 2014

Cervical Cancer - Pipeline Review, H1 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 274 pages

Cervical Cancer - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Cervical Cancer - Pipeline Review, H1 2014’, provides an overview of the Cervical Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cervical Cancer - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cervical Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Cervical Cancer - Overview 11
Pipeline Products for Cervical Cancer - Comparative Analysis 12
Cervical Cancer - Therapeutics under Development by Companies 13
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 18
Cervical Cancer - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Cervical Cancer - Products under Development by Companies 25
Cervical Cancer - Products under Investigation by Universities/Institutes 29
Cervical Cancer - Companies Involved in Therapeutics Development 30
F. Hoffmann-La Roche Ltd. 30
Helix BioPharma Corp. 31
Sanofi 32
GlaxoSmithKline plc 33
Nektar Therapeutics 34
Gilead Sciences, Inc. 35
Daiichi Sankyo Company, Limited 36
Amorfix Life Sciences Ltd. 37
MediGene AG 38
Nanotherapeutics, Inc. 39
Arbor Vita Corporation 40
Novartis AG 41
Chong Kun Dang Pharmaceutical Corp. 42
Taiho Pharmaceutical Co., Ltd. 43
Zeria Pharmaceutical Co Ltd 44
Genmab A/S 45
CEL-SCI Corporation 46
Advaxis, Inc. 47
3SBio Inc. 48
Dendreon Corporation 49
Transgene SA 50
Antigen Express, Inc. 51
Shantha Biotechnics Limited 52
Bionor Pharma ASA 53
Med Discovery SA 54
Priaxon AG 55
ApoVax, Inc. 56
PDS Biotechnology Corporation 57
Azaya Therapeutics Incorporated 58
Merrimack Pharmaceuticals, Inc. 59
Genexine, Inc. 60
Genticel 61
Genetic Immunity, Inc 62
Sirnaomics, Inc. 63
Advanced Cancer Therapeutics 64
Xenova Group plc 65
Mycenax Biotech Inc. 66
EyeGene, Inc. 67
Vaccibody AS 68
Wellstat Biologics Corporation 69
ISA Pharmaceuticals B.V. 70
Indian Immunologicals Limited 71
Coridon Pty Ltd 72
Redbiotec AG 73
CZ BioMed Corp 74
LondonPharma Ltd 75
Formune S.L. 76
Centre de Regulacio Genomica 77
Cervical Cancer - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Target 80
Assessment by Mechanism of Action 84
Assessment by Route of Administration 88
Assessment by Molecule Type 90
Drug Profiles 93
hot water extract of mycobacterium tuberculosis - Drug Profile 93
bevacizumab - Drug Profile 94
(tegafur + gimeracil + oteracil potassium) - Drug Profile 98
etirinotecan pegol - Drug Profile 101
interferon alpha-2b - Drug Profile 104
ADXS-HPV - Drug Profile 105
ProCervix - Drug Profile 108
hot water extract of mycobacterium tuberculosis - Drug Profile 109
celecoxib - Drug Profile 110
Triapine - Drug Profile 111
exatecan mesylate - Drug Profile 113
buparlisib hydrochloride - Drug Profile 115
nimotuzumab - Drug Profile 118
GSK-2141795 + trametinib - Drug Profile 121
TG-4001 - Drug Profile 123
pazopanib hydrochloride - Drug Profile 125
CIGB-228 Vaccine - Drug Profile 129
CIGB-300 - Drug Profile 130
nedaplatin + [paclitaxel albumin-bound] - Drug Profile 132
TA-HPV Vaccine - Drug Profile 133
mapatumumab - Drug Profile 134
artemether - Drug Profile 137
HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - Drug Profile 138
ISA-101 - Drug Profile 139
HuMax-TF ADC - Drug Profile 140
PDS-0101 - Drug Profile 141
docetaxel liposomal - Drug Profile 142
Leukocyte Interleukin Injection - Drug Profile 144
everolimus - Drug Profile 146
GSK-2256098 - Drug Profile 150
EG-HPV - Drug Profile 151
CKD-12201 - Drug Profile 152
GX-188-E - Drug Profile 153
PEK Fusion Protein Vaccine - Drug Profile 154
PV-701 - Drug Profile 155
GSK-2849330 - Drug Profile 156
Lovaxin S - Drug Profile 157
MDRG-01 - Drug Profile 158
SAR-566658 - Drug Profile 159
Drug Targeting Carbonic Anhydrase IX - Drug Profile 161
SSS-08 Vaccine - Drug Profile 162
irinotecan sucrosofate liposomal - Drug Profile 163
ApoVax-104-HPV - Drug Profile 166
HPV Vaccine - Drug Profile 167
BN-500001 - Drug Profile 168
RBT-201 - Drug Profile 169
Squamous Antibodies - Drug Profile 170
cidofovir - Drug Profile 171
AEH-10p - Drug Profile 172
AAVLP Program - Drug Profile 173
Cervlysis - Drug Profile 174
Human Papillomavirus Vaccine - Drug Profile 175
HPV Vaccine - Drug Profile 176
VB-1016 - Drug Profile 177
EDA-HPVE7 - Drug Profile 179
Cell Therapy For Cervical Carcinoma - Drug Profile 181
Vvax-001 - Drug Profile 182
BPR-1K653 - Drug Profile 183
TF-011-Monomethyl Auristatin E - Drug Profile 184
Allogenic Mesenchymal Stem Cells - Drug Profile 186
Beta Catenin Inhibitors - Drug Profile 187
Vac-CRT/E7 Vaccine - Drug Profile 188
MTDIA - Drug Profile 189
VLP-E7 Vaccine - Drug Profile 190
Crocetin - Drug Profile 191
HupaDerm Vaccine - Drug Profile 193
AMF-3d-19 - Drug Profile 194
E6-p53 Inhibitors - Drug Profile 195
CX-99 - Drug Profile 196
STP-909 - Drug Profile 197
Small Molecules to Inhibit Bcl-2 for Infectious Disease and Oncology - Drug Profile 198
RNA Aptamer - Drug Profile 199
NMK-TD-100 - Drug Profile 200
NSC-73306 - Drug Profile 201
BH3 Peptides - Drug Profile 202
Anti-P4.33 Antibody - Drug Profile 203
Drugs to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 204
DR5-Receptor Specific TRAIL Mutant Protein - Drug Profile 205
MIS Type II Receptor Activators for Oncology - Drug Profile 206
AVC-7 - Drug Profile 207
Vacc-HPV - Drug Profile 208
Oral Cervical Cancer Vaccine - Drug Profile 209
Cervical Cancer - Recent Pipeline Updates 210
Cervical Cancer - Dormant Projects 257
Cervical Cancer - Discontinued Products 258
Cervical Cancer - Product Development Milestones 259
Featured News and Press Releases 259
Appendix 267
Methodology 267
Coverage 267
Secondary Research 267
Primary Research 267
Expert Panel Validation 267
Contact Us 268
Disclaimer 268

List of Tables

Number of Products under Development for Cervical Cancer, H1 2014 17
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 20
Number of Products under Development by Companies, H1 2014 (Contd..1) 21
Number of Products under Development by Companies, H1 2014 (Contd..2) 22
Number of Products under Development by Companies, H1 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2014 25
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 26
Comparative Analysis by Late Stage Development, H1 2014 27
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Development, H1 2014 29
Comparative Analysis by Unknown Stage Development, H1 2014 30
Products under Development by Companies, H1 2014 31
Products under Development by Companies, H1 2014 (Contd..1) 32
Products under Development by Companies, H1 2014 (Contd..2) 33
Products under Development by Companies, H1 2014 (Contd..3) 34
Products under Investigation by Universities/Institutes, H1 2014 35
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 36
Cervical Cancer - Pipeline by Helix BioPharma Corp., H1 2014 37
Cervical Cancer - Pipeline by Sanofi, H1 2014 38
Cervical Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 39
Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2014 40
Cervical Cancer - Pipeline by Gilead Sciences, Inc., H1 2014 41
Cervical Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 42
Cervical Cancer - Pipeline by Amorfix Life Sciences Ltd., H1 2014 43
Cervical Cancer - Pipeline by MediGene AG, H1 2014 44
Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2014 45
Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2014 46
Cervical Cancer - Pipeline by Novartis AG, H1 2014 47
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 48
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 49
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2014 50
Cervical Cancer - Pipeline by Genmab A/S, H1 2014 51
Cervical Cancer - Pipeline by CEL-SCI Corporation, H1 2014 52
Cervical Cancer - Pipeline by Advaxis, Inc., H1 2014 53
Cervical Cancer - Pipeline by 3SBio Inc., H1 2014 54
Cervical Cancer - Pipeline by Dendreon Corporation, H1 2014 55
Cervical Cancer - Pipeline by Transgene SA, H1 2014 56
Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2014 57
Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H1 2014 58
Cervical Cancer - Pipeline by Bionor Pharma ASA, H1 2014 59
Cervical Cancer - Pipeline by Med Discovery SA, H1 2014 60
Cervical Cancer - Pipeline by Priaxon AG, H1 2014 61
Cervical Cancer - Pipeline by ApoVax, Inc., H1 2014 62
Cervical Cancer - Pipeline by PDS Biotechnology Corporation, H1 2014 63
Cervical Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2014 64
Cervical Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 65
Cervical Cancer - Pipeline by Genexine, Inc., H1 2014 66
Cervical Cancer - Pipeline by Genticel, H1 2014 67
Cervical Cancer - Pipeline by Genetic Immunity, Inc, H1 2014 68
Cervical Cancer - Pipeline by Sirnaomics, Inc., H1 2014 69
Cervical Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2014 70
Cervical Cancer - Pipeline by Xenova Group plc, H1 2014 71
Cervical Cancer - Pipeline by Mycenax Biotech Inc., H1 2014 72
Cervical Cancer - Pipeline by EyeGene, Inc., H1 2014 73
Cervical Cancer - Pipeline by Vaccibody AS, H1 2014 74
Cervical Cancer - Pipeline by Wellstat Biologics Corporation, H1 2014 75
Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2014 76
Cervical Cancer - Pipeline by Indian Immunologicals Limited, H1 2014 77
Cervical Cancer - Pipeline by Coridon Pty Ltd, H1 2014 78
Cervical Cancer - Pipeline by Redbiotec AG, H1 2014 79
Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2014 80
Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2014 81
Cervical Cancer - Pipeline by Formune S.L., H1 2014 82
Cervical Cancer - Pipeline by Centre de Regulacio Genomica, H1 2014 83
Assessment by Monotherapy Products, H1 2014 84
Assessment by Combination Products, H1 2014 85
Number of Products by Stage and Target, H1 2014 88
Number of Products by Stage and Mechanism of Action, H1 2014 92
Number of Products by Stage and Route of Administration, H1 2014 95
Number of Products by Stage and Molecule Type, H1 2014 98
Cervical Cancer Therapeutics - Recent Pipeline Updates, H1 2014 216
Cervical Cancer - Dormant Projects, H1 2014 263
Cervical Cancer - Discontinued Products, H1 2014 264

List of Figures
Number of Products under Development for Cervical Cancer, H1 2014 17
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 19
Number of Products under Investigation by Universities/Institutes, H1 2014 24
Comparative Analysis by Clinical Stage Development, H1 2014 28
Comparative Analysis by Early Stage Products, H1 2014 29
Assessment by Monotherapy Products, H1 2014 84
Assessment by Combination Products, H1 2014 85
Number of Products by Top 10 Target, H1 2014 86
Number of Products by Stage and Top 10 Target, H1 2014 87
Number of Products by Top 10 Mechanism of Action, H1 2014 90
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 91
Number of Products by Top 10 Route of Administration, H1 2014 94
Number of Products by Stage and Top 10 Route of Administration, H1 2014 95
Number of Products by Top 10 Molecule Type, H1 2014 96
Number of Products by Stage and Top 10 Molecule Type, H1 2014 97

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for Lung Cancer: Global Markets

Diagnostics and Therapeutics for Lung Cancer: Global Markets

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research report analyzes the market for diagnostics and therapeutics for lung cancer, and also focuses on regulations and reimbursements affecting diagnostics tests and drugs used in therapeutics. ...

Bladder Cancer Treatment Drugs Markets in China

Bladder Cancer Treatment Drugs Markets in China

  • $ 4 000
  • Industry report
  • June 2015
  • by Asia Market Information & Development Company

China's demand for Bladder Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Cancer Treatment Drugs Markets in China

Cancer Treatment Drugs Markets in China

  • $ 4 000
  • Industry report
  • June 2015
  • by Asia Market Information & Development Company

China's demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...


Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US, Weekly Update

  • July 2015
    12 pages
  • Pathology  

  • United States  

View report >

Pathology Description in the UK

  • July 2015
    2 pages
  • Cancer  

    Oncology  

    Breast Cancer  

  • United Kingdom  

View report >

Cola Markets in the US

  • July 2015
    12 pages
  • Cola  

    Sugar  

    Energy Drink  

  • United States  

    World  

View report >

Related Market Segments :

Cancer
Pharmaceutical
Oncology
Cervical Cancer
Drug

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.